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Abstract
In multiple myeloma (MM) osteolytic lesions rarely heal because of persistent suppressed 
osteoblast differentiation resulting in a high fracture risk. Herein, chromatin immunoprecipitation 
analyses reveal that MM cells induce repressive epigenetic histone changes at the Runx2 locus that 
prevent osteoblast differentiation. The most pronounced MM-induced changes were at the Runx2-
P1 promoter, converting it from a poised bivalent state to a repressed state. Previously it was 
observed that MM induce the transcription repressor GFI1 in osteoblast precursors, which 
correlates with decreased Runx2 expression. Thus, prompting detailed characterization of the MM 
and TNFα-dependent GFI1-response element within the Runx2-P1 promoter. Further analyses 
reveal that MM-induced GFI1 binding to Runx2 in osteoblast precursors and recruitment of the 
histone modifiers HDAC1, LSD1, and EZH2 is required to establish and maintain Runx2 
repression in osteogenic conditions. These GFI1-mediated repressive chromatin changes persist 
even after removal of MM. Ectopic GFI1 is sufficient to bind to Runx2, recruit HDAC1 and EZH2, 
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increase H3K27me3 on the gene, and prevent osteogenic induction of endogenous Runx2 
expression. Gfi1 knockdown in MC4 cells blocked MM-induced recruitment of HDAC1 and 
EZH2 to Runx2, acquisition of repressive chromatin architecture, and suppression of OB 
differentiation. Importantly, inhibition of EZH2 or HDAC1 activity in pre-osteoblasts after MM 
exposure in vitro or in osteoblast precursors from MM patients reversed the repressive chromatin 
architecture at Runx2 and rescued osteoblast differentiation.
Implications—This study suggests that therapeutically targeting EZH2 or HDAC1 activity may 
reverse the profound MM-induced osteoblast suppression and allow repair of the lytic lesions.
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Introduction
Multiple myeloma (MM), a malignant plasma cell disorder, is the most frequent cancer to 
involve bone (1). Over 80% of MM patients develop bone lesions that can result in severe 
pain and frequent pathological fractures (2), a major contributor to patient morbidity and 
mortality (3). MM bone disease is characterized by increased osteolytic bone destruction 
with little or no new bone formation due to persistent MM-induced suppression of bone 
marrow stromal cell (BMSC) differentiation into bone-forming osteoblasts (OB) (4, 5). This 
results in lesions that rarely heal, even when patients are in long-term remission. Further, 
BMSC from MM patients (MM-BMSC) or mouse MM models, and healthy donor BMSC 
(HD-BMSC) and pre-OB cell lines exposed to MM cells in culture, demonstrate decreased 
OB differentiation even after removal of the MM cells and extended culture (6). This 
protracted selective suppression of OB differentiation suggests that MM cells induce a 
persistent, cell-autonomous change in MM-BMSC. MM-derived TNFα, CCL3, IL3/activin 
A, Dickkopf1, sclerostin, TGFβ, HGF, and IL7, as well as direct contact, contribute to OB 
suppression (4, 7), but the mechanisms responsible for the sustained cell-autonomous 
blockade of OB differentiation in the MM-BMSC are not well understood. MM altered 
BMSC also support MM cell adhesion, growth, and chemoresistance via increased levels of 
adhesion molecules, chemokines, and cytokines, and express an altered RANKL(TNFSF11)/
osteoprotegerin ratio to favor osteoclastogenesis (8–12).
OB differentiation requires upregulation and activation of the critical transcription factor 
RUNX2/CBFA1/AML3 (RUNX2) (13). We (6), and others (14), have shown that RUNX2 
activity in OB precursors is inhibited in MM, but the mechanism is unclear. Our previous 
studies of MM-exposed BMSC revealed that Runx2 gene repression was correlated with 
elevated expression of growth factor independence 1 (GFI1), a transcription repressor (6). 
We found that BMSC isolated from Gfi1−/− mice were significantly resistant to MM-induced 
suppression of Runx2. Further, siRNA Gfi1 knockdown in MM-BMSCs restored expression 
of RUNX2 and OB differentiation markers osteocalcin (OCN, BGLAP) and bone 
sialoprotein (BSP, IBSP). These studies suggested that GFI1 could be a novel therapeutic 
target for MM bone disease. However, therapeutic targeting of transcription factors is 
difficult and GFI1 is a large multi-functional protein with multiple modes of action.
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GFI1, a 55 kD zinc-finger containing member of the Snail/Gfi1 transcription repressor 
family that includes GFI1b, SNAIL (SNAI1), SLUG (SNAI2), IA-1 (INSM1), and MLT1 
(ISMN2) (15, 16), has diverse biological functions and mechanisms of action, and regulates 
various aspects of normal and malignant hematopoiesis as well as inner ear development 
(17, 18). The 422 aa human (423 aa murine) GFI1 contains an N-terminal SNAG domain, an 
unstructured intermediate domain, and 6 C-terminal C2-H2 Zn finger domains, of which Zn 
fingers 3–5 are required for sequence-specific DNA binding to a recognition sequence 
containing the “AA(T/G)C” core motif (15, 19). GFI1 interacts with various chromatin 
modifiers to mediate epigenetic repression of target genes. The GFI1 SNAG domain is 
critical in recruiting lysine specific demethylase 1 (LSD1, KDM1A) with the REST 
corepressor (CoREST, RCOR1) to target genes regulating hematopoiesis (20). GFI1 
recruitment of histone methyltransferase G9a (EHMT2) and histone deacetylase 1 (HDAC1) 
through the intermediate domain represses the promoter of cell cycle regulator CDKN1A 
(21). GFI1 can also repress gene expression independently of its DNA binding capability, as 
shown by its binding to and cooperation with the POZ-ZF transcription factor MIZ-1 
(ZBTB17) at the CDKN1A and CDKN2B gene promoters (11, 22). Additionally, GFI1 
binding to other transcription factors can interfere with their DNA binding or transactivation 
properties, thereby repressing their targets without GFI1 DNA binding. For instance, GFI1 
can antagonize binding of RELA to its target genes in LPS-stimulated macrophages (23), as 
well as inhibit PU.1 (SPI1)-dependent gene transcription during granulocyte development 
(24). Conversely, GFI1 enhances STAT3-mediated gene transactivation by interacting with 
and sequestering a STAT3-negative regulator PIAS3 (25). GFI1 also regulates gene 
expression of the T-cell receptor CD45 (PTPRC) at the level of alternative splicing by 
interacting with the splicing factor U2AF26 (U2AFIL4) (26). Thus, further study was 
necessary to understand how GFI1 influenced Runx2 expression.
In the current study, we determined if MM cells induce GFI1-mediated epigenetic changes 
in the chromatin architecture of the Runx2 locus in OB precursors. We identified the 
chromatin modifiers recruited by GFI1 and explored if inhibition of these enzymatic 
activities could induce reversal of the persistent suppression of BMSC to osteogenic 
differentiation, making them potential actionable therapeutic targets to improve bone health 
in MM patients.
Materials And Methods
Reagents
Reagents used in this study can be found in Supplementary Methods.
Cells and co-culture
All cultures described below contained 10% FCS-1% pen/strep. The pre-OB murine cell line 
MC3T3-E1 subclone-4 (MC4) was obtained from Dr. Guozhi Xiao (27, 28) in 2009 and 
subclone-14 (MC14) was obtained from ATCC (CRL-2594) in 2014. Both were maintained 
in ascorbic acid-free αMEM proliferation media. Murine 5TGM1-GFP-TK (5TGM1) MM 
cells (6) and human MM1.S-GFP cells (11) were maintained in RPMI1640. Cell lines were 
authenticated by morphology, gene expression profile, and tumorigenic capacity (MM cells). 
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MC4 cells were grown to 90% confluency prior to co-culture. Direct 5TGM1-MC4 (10:1) 
co-cultures and indirect co-cultures of MM1.S cells in transwells (10:1) with MC14 cells 
were carried out in 50:50 RPMI1640/αMEM proliferation media. MM1.S in transwells 
(Corning Inc., 3450) or 5TGM1 cells were carefully removed (FACS analysis demonstrated 
that ≤ 1% 5TGM1 cells remained). The MC4 and MC14 cells were isolated immediately or 
subjected to OB differentiation first. Scrambled control (SHC002, Sigma) and mouse Gfi1 
shRNA (Sigma, TRCN0000096706, 5’-CCTCATCACTCATAGCAGAAA-3’) in pLKO.1-
puro lentiviruses were generated by the UPCI lentivirus core facility and used to stably 
transduce (with polybrene) MC4 cells, which were selected and maintained using puromycin 
(2.5 μg/mL).
Human samples and primary BMSC cultures
BM aspirates and MM bone resections were collected in heparin from 15 healthy donors and 
29 MM patients. Human studies were approved by the University of Pittsburgh and Indiana 
University IRBs. Samples were collected from participants after obtaining written informed 
consent in accordance with the Declaration of Helsinki. BM mononuclear cells were 
separated by Ficoll-Hypaque density sedimentation and the nonadherent cells removed after 
overnight incubation in IMDM-10%FCS. The adherent cultures were then continued for 21 
d with media changes every 4 d to obtain BMSC. Subconfluent cells were detached with 
trypsin and replated (105 cells/10-cm dish) for use at passage 2 and 3.
OB differentiation, and alkaline phosphatase and alizarin red assays
OB differentiation media (αMEM supplemented with 50 μg/ml ascorbic acid and 10 mM β-
glycerophosphate; for human cells 10 nM Dex was also added) was added to primary BMSC 
or MC4 cells with or without prior MM exposure; media was changed every 3 d. 
Mineralization at times indicated was assessed using alizarin red staining (6). The staining 
density quantitation was carried out using a ProteinSimple FluorChem™ M imaging system.
DNAs
Construction of the -974/+111 mRunx2 P1 promoter-pGL4.10[luc2] reporters containing 
either wildtype, Δ-37/-7, or the GFI1 site mutations (L mutant GGGCTT, R mutant 
AAGCCC, and LR mutant GGGCCC) and generation of the expression vectors encoding 
Myc-tagged mGFI1-1-423 aa, -1-380 aa or -239-423 aa (in pCS2-MT) from mGFI1-wt-
pCDNA3.1 are detailed in the Supplementary Methods. All constructs were verified by 
DNA sequencing.
Transfection of Runx2 P1 promoter-Luc reporters and GFI1 constructs
The mRunx2 P1 promoter-reporters and pRL-TK plasmids (Promega) were transfected into 
MC4 cells with Lipofectamine2000, along with empty (EV) or wt mGFI1 expression 
vectors, or treated with TNFα as indicated in Figure legends. Luc and renilla activities were 
measured in supernatants from lysed cells (48 h) using the Dual-Luciferase® Reporter 
Assay System (Promega). The normalized (to renilla) relative Luc activities for each reporter 
construct were calculated as a percent of the activity of the -974/+111 mRunx2-
pGL4.10[luc2]-wt co-transfected with EV. Transfections of Myc-mGFI1-wt and Myc-
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mGFI1-deletions into MC4 for endogenous Runx2 mRNA and ChIP analyses were carried 
using FugeneHD (E2311, Promega). See Supplementary methods for more details.
Protein lysates and Western blotting
Transfected MC4 cell cultures were treated with 1X lysis buffer (Cell Signaling) to make 
whole cell lysates, which were examined by western blotting with primary antibodies as 
indicated. The membranes were then incubated with secondary chemiluminescent antibodies 
and imaged using a ProteinSimple FluorChem™ M imaging system. Quantitation of protein 
band densities was performed using the alpha view analysis software package.
Real-time quantitative PCR (qPCR) RNA expression analyses
MC4 RNA was isolated using TRIzol reagent and converted to cDNA using First-Strand 
cDNA Synthesis System (Life Technologies, 11904-018). qPCR was carried out using 2x 
Maxima SYBR Green/ROX qPCR Master Mix (K0223, Thermo Fisher) in Fast 96-Well 
Reaction Plates (Applied Biosystems) using a StepOnePlus (Applied Biosystems). Relative 
mRNA levels were calculated using the ΔΔCt method using 18SrRNA for normalization. 
The qPCR primers are listed in Table S1.
ChIP assay
Chromatin from MC4 cells, MM-BMSC, and HD-BMSC was analyzed using a modification 
of the ChIP Millipore/Upstate protocol (MCPROTO407) as described (29) using Magna 
ChIP Protein A+G Beads (16-663, Millipore). In brief, a total of 2x107 cells were fixed in 
1% formaldehyde (F79-500, Fisher) for 10 min at room temperature. Samples were 
sonicated (to generate DNA fragments of 250 base pairs (bp) average length) on ice using a 
Fisher Scientific Sonic Dismembrator (Model 100) and centrifuged at 12000 RPM for 10 
min. Chromatin from 4x106 cells was diluted 7-fold in ChIP Dilution Buffer (0.01% SDS, 
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH8.1, 167 mM NaCl) and 
incubated at 4°C overnight with respective antibodies. Aliquots for input and non-specific 
IgG control samples were included with each experiment. IgG ChIP was run on untreated 
MC4 samples. ChIP-qPCR primers are listed in Table S2. Fold enrichment was calculated 
based on Ct as 2(ΔCt), where ΔCt = (CtInput –CtIP). The IgG ΔCt Ct was subtracted from the 
specific Ab ΔCt to generate ΔΔCt = (ΔCtspecific Ab − ΔCtIgG).
Statistical Analysis
All experiments were repeated at least two independent times. Most data is presented as 
biological triplicates and results reported as means±SD unless otherwise stated. Statistical 
significance was evaluated by either the Student’s t test or one-way ANOVA with Tukey’s 
multiple comparison post-test using Graphpad Prism 6 as indicated. Degree of significance 
is represented using ρ values: *= ρ≤0.05, **= ρ≤0.01, ***= ρ≤0.001, ****= ρ≤0.0001 
(Different symbols may be used to reflect multiple two-way comparisons).
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Results
MM induces sustained transcriptional and epigenetic suppression of the mRunx2 
promoter in murine pre-OB cells
We (Supplementary Fig. S1), and others (30) demonstrated that MM cells and TNFα cause a 
very rapid decrease of Runx2 mRNA mediated by decreasing Runx2 mRNA half-life. 
However, since maintenance and propagation of gene silencing is often controlled at the 
chromatin level, we hypothesized that the long-term suppression of OB differentiation in the 
MM microenvironment results from epigenetic repression of Runx2 transcription in BMSC. 
Therefore, we analyzed the effect of 5TGM1-MM cell exposure on RNA Polymerase II (Pol 
II) occupancy and the histone H3 methylation and acetylation profiles along the murine 
(m)Runx2 locus during MC3T3-E1 subclone-4 (MC4) cell proliferation and OB 
differentiation (Fig. 1A) using ChIP-qPCR (Fig. 1B) amplicons as indicated. We found that 
MC4 exposure to 5TGM1 inhibited the OB-induced recruitment of Pol II to the mRunx2-P1 
promoter (Fig. 1C, amplicons 3 and 4), as well as decreased elongating Pol II (marked by 
Ser2 phosphorylation of the C-terminal domain; Ser2P CTD) downstream of the mRunx2-
P1 promoter (Fig. 1D), thus demonstrating that MM exposure down-regulates mRunx2 
transcription in MC4 cells. Paused Pol II was not evident at the mRunx2-P2 promoter (Fig. 
1C, amplicons 8ABC), but transiting Pol II there was elevated by OB differentiation and 
decreased by MM exposure (Fig. 1D). Further evidence of prior MM exposure leading to 
inhibition of mRunx2 transcription during OB induction is revealed by decreased 
enrichment of tri-methylated H3K36 (H3K36me3) towards the 3’ end of the mRunx2 gene 
(Fig. 1E), which marks the Pol II elongation footprint (31). However, MM-exposure did not 
affect presence of Pol II, Ser2P CTD, and H3K36me3 at mRunx2 in proliferating MC4 (Fig. 
1C–E). The permissive chromatin marks, acetylation at H3K9 (H3K9ac) (Fig. 1F) and 
methylation at H3K4 (H3K4me3) (Fig. 1G), were abundant at both mRunx2 promoters prior 
to OB stimulus, reflecting the poised and basal/constitutive transcription levels in MC4 cells. 
These marks increased following differentiation (more so at P1 than at P2), consistent with 
increased mRunx2 activation. MM-exposure significantly reduced the H3K9ac and 
H3K4me3 levels at mRunx2-P1 in proliferating MC4 (d0) and they were refractory to 
elevation by OB differentiation induction (d4). In contrast, MM cells upregulated mIl6 
mRNA in proliferating MC4, with increased Pol II occupancy and H3K9ac, H3K4me3, and 
H3K36me3 levels at the mIl6 gene (Supplementary Fig. S2). There is more of the repressive 
H3K27 tri-methylation (H3K27me3) (32) mark on the mRunx2-P1 promoter than mRunx2-
P2 in proliferating cells (Fig. 1H), reflecting the bivalent nature of the poised P1 promoter. 
Furthermore, MM increased H3K27me3 only at the mRunx2-P1 promoter in MC4 (Fig. 
1H), which remained elevated four days after MM cell removal. These data indicate that 
MM exposure reduced the transcriptionally permissive bivalent chromatin architecture of the 
mRunx2-P1 promoter in MC4 cells, marked by high H3K9ac and H3K4me3 levels along 
with H3K27me3, and induced a more repressive H3K27me3-prevalent signature.
Myeloma induces recruitment of GFI1 to the mRunx2 promoter in pre-OB
Since we had shown an inverse correlation with GFI1 levels and Runx2 expression (6), we 
postulated that GFI1 is directly responsible for the MM-induced epigenetic changes by 
binding at the Runx2 gene and recruiting various co-repressors to establish epigenetic 
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silencing. Therefore, we first needed to establish if GFI1 binds the Runx2 gene. Using Gfi1-
WT cotransfections with a set of 5’ and 3’ deletions, as well as internal deletions, of 
mRunx2-pGL4.10[luc2] reporters, we localized the GFI1-responsivity to the -37/-7 region 
(Supplementary Fig. S3A,B). There is no consensus GFI1 binding site (15, 19) in the 
-108/-1 mRunx2 promoter, but the region contains 6 GFI1 binding site cores (AA(T/G)C). 
Therefore, we used a combination of biotin-oligo (B-oligo) streptavidin agarose bead pull-
down assays (Supplementary Fig. S3C–G) and EMSA (Supplementary Fig. S3H,I) to 
establish that GFI1 binds at an overlapped palindromic pair of GFI1 cores at -21/-18 (L) and 
-19/-16 (R). Mutation of either core decreased GFI1 binding, but mutation of both (LR) 
ablated binding (Supplementary Fig. S3G,H). GFI1 cotransfected into MC4 with -974/+111 
mRunx2-pGL4.10[luc2] reporters containing site-specific mutations (L, R, and LR) of the 
-21/-16 double core GFI1 binding site (Fig. 2A) showed that the two single site mRunx2 
mutants (L, R) were partially resistant to GFI1, and the double LR mutant and the Δ-37/-7 
mRunx2 deletion were entirely resistant (Fig. 2B). Similar results with this set of mRunx2 
reporters were obtained using TNFα treatment to repress mRunx2 (Fig. 2C), although the 
rescue from TNFα repression is only about 60% with LR or Δ-37/-7. This may indicate that 
a weaker GFI1 binding site at -67/-64 may also play a role in TNFα repression of Runx2 or 
that another factor is involved. Western blots analysis of the expression of transfected GFI1 
protein deletions in HEK293 cells established that the mutant myc-mGFI1 proteins were all 
expressed as well or better than mGFI1-WT (Input), and -40/-1 B-oligo pulldowns using 
these extracts demonstrated that only mGFI1-WT and mGFI1;239-423 bound DNA 
(Supplementary Fig. S4A). Co-transfection of mGFI1-WT, mGFI1;239-423 (lacking 
recruitment domains for many corepressors) and mGFI1;1-380 (lacking the C-terminal 43aa 
and doesn’t bind DNA) expression plasmids with the -974/+111 mRunx2-pGL4.10[luc2] 
reporter revealed that neither mutant mGFI1 could repress reporter expression although they 
were expressed at similar levels as mGFI1-WT (Fig. 2D).
Consistent with the reporter experiments, we observed that ectopic mGFI1 dose-dependently 
decreased endogenous mRunx2 mRNA in proliferating undifferentiated MC4 cells (Fig. 
3A), indicating that increased GFI1 was sufficient for endogenous mRunx2 repression. The 
increased GFI1 did not alter expression of Sp1, Il6 or the RUNX2 targets Osx (Sp7), Ocn 
and Bsp (Supplementary Fig. 4B); the latter because these genes were not yet stimulated. We 
analyzed the capacity of ectopic mGFI1-WT and mGFI1-deletions (1-380 and 239-423) to 
bind (Fig. 3B) and regulate endogenous mRunx2 expression (Fig. 3C). ChIP-qPCR analysis 
demonstrated ectopic mGFI1-WT and mGFI1;239-423 occupancy on the endogenous 
mRunx2 promoter in MC4 cells using amplicon-3 (centered on -36) that included the 
-21/-16 GFI1 sites, whereas mGFI1;1-380 did not bind (Fig. 3B). Further, mGFI1-WT 
repressed endogenous mRunx2 expression; while neither mGFI1;1-380 nor mGFI1;239-423 
was able to repress mRunx2 expression (Fig. 3C). A ChIP-qPCR scan for ectopic GFI1-WT 
binding along the Runx2 gene showed that it did not bind near the Runx2-P2 promoter 
(Supplementary Fig. 4C). Kinetic ChIP-qPCR analyses of MM-exposed MC4 cells revealed 
that endogenous GFI1 recruitment to mRunx2-P1 is not detectable until 36-h of MM 
treatment with increased occupancy at 48-h (Fig. 3D).
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GFI1 recruits chromatin co-repressors to induce epigenetic suppression of the Runx2 
promoter in myeloma-exposed pre-OB
The pleiotropic effects of GFI1-targeted epigenetic gene repression are associated with its 
recruitment of various histone co-repressors (20, 21, 33). Since we demonstrated that MM 
cells induce recruitment of endogenous GFI1 to the Runx2 gene (Fig. 3D,E) with 
concomitant epigenetic repression of the Runx2 locus (Fig. 1C–H), we screened for MM-
induced occupancy of chromatin modifiers near the GFI1 binding site in mRunx2 in pre-
OBs. MM treatment induced HDAC1 and LSD1 (Fig. 3E) binding to the mRunx2 promoter 
in MC4 cells, which is consistent with the observed decrease in transcription activation 
marks H3K9ac and H3K4me3 (Fig. 1). Since we detected a significant MM-induced 
increase in H3K27me3 levels at mRunx2 (Fig. 1H), we used ChIP to confirm MM-induced 
occupancy of EZH2, the methyltransferase component of the polycomb repressive complex 
2 (PRC2) responsible for generating H3K27me3 (34), near the mRunx2 GFI1 binding site 
(Fig. 3E).
Ectopically expressed Myc-mGFI1-WT in MC4 cells resulted in recruitment of the histone 
modifiers HDAC1 and EZH2 to the mRunx2 amplicon-3 (Fig. 3F), thus demonstrating that 
GFI1 is capable of recruiting these co-repressors to mRunx2 in the absence of MM signals. 
Further, the increased recruitment of endogenous EZH2 resulted in enhanced deposition of 
the repressive H3K27me3 mark (Fig. 3F).
GFI1 is required for MM-induced recruitment of repressive chromatin modifiers to the 
Runx2 gene in pre-OB
The direct involvement of MM-induced GFI1 recruitment of epigenetic co-repressors was 
further delineated using a stable Gfi1 knockdown MC4 cell line (shGfi1-MC4) (Fig. 4A), 
with ~50% reduction in GFI1 protein levels (Supplementary Fig. S4D). 5TGM1-MM co-
culture with control shSCR-MC4 resulted in the expected reduction of mRunx2 mRNA 
expression (Fig. 4B). MM co-culture with shGfi1-MC4 still resulted in a rapid decrease in 
mRunx2 mRNA (Fig. 4B d0), likely due to mRNA destabilization. However, decreased 
GFI1 prevented the sustained mRunx2 repression observed following induction of OB 
differentiation (Fig. 4B d4). Further, RUNX2 target genes mOcn and mBsp also exhibited 
significant resistance to MM inhibition in shGfi1-MC4 compared to SCR-MC4 (Fig. 4C,D). 
Alkaline phosphatase (mAlpl) expression trended up, but the change was not significant 
(Fig. 4E). Consistent with the MM-resistant mRunx2 mRNA expression in shGfi1-MC4, 
lack of MM-induced GFI1 binding to the mRunx2 promoter (Fig. 4F) results in deficient 
recruitment of co-repressors HDAC1 (Fig. 4G) and EZH2 (Fig. 4H). Further, lack of GFI1-
mediated HDAC1 and EZH2 recruitment rescued levels of H3K9ac at mRunx2 after MM 
co-culture (Fig. 4I). Concomitantly, we observed significantly reduced enrichment of the 
repressive mark H3K27me3 (Figure 4J), further arguing for the importance of GFI1-directed 
EZH2 recruitment to the mRunx2 promoter in pre-OB during MM co-culture conditions. 
Thus lack of GFI1 recruitment directly correlates with the inability of the MM cells to 
induce epigenetic suppression of the mRunx2 promoter. These results reveal that 
destabilization of mRunx2 mRNA is not sufficient to prevent OB differentiation in the 
absence of GFI1-mediated epigenetic alteration of the mRunx2 gene.
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MM suppression of mRunx2 and OB differentiation of MC4 cells is reversed by HDAC1 or 
EZH2 inhibition
We used small molecule inhibitors of HDAC1 (MC1294) and EZH2 (GSK126) enzymatic 
activities to investigate if the MM-induced GFI1-mediated epigenetic repression of mRunx2 
is reversible. Following 5TGM1-MC4 co-cultures in proliferation media, we removed the 
MM cells and subjected the MC4 cells to OB differentiation in the presence of either 
vehicle, MC1294 or GSK126 (Fig. 5). Western analyses demonstrated that the HDAC 
inhibitor MC1294 increased global H3K9Ac levels in MC4 cells after 2 days regardless of 
whether or not the cells had been pre-exposed to MM cells, while not affecting the H3, 
HDAC1, EZH2, or H3K27me3 levels (Fig. 5A). Similarly, the EZH2 inhibitor GSK126 
decreased global H3K27me3 levels in MC4 cells after 2 days without affecting H3, EZH2, 
HDAC1, and H3K9ac levels (Fig. 5B). MC4 treatment with MC1294 or GSK126 did not 
alter standard OB differentiation-stimulated mRunx2 mRNA expression at d4 (Fig. 5C). 
However, inhibition of HDAC1 or EZH2 activity significantly rescued mRunx2 mRNA from 
the MM-mediated sustained repression at d4 (Fig. 5C). HDAC1 and EZH2 inhibition 
similarly rescued mRNA expression of several downstream RUNX2 targets critical for OB 
differentiation, including mOcn, mBsp and mAlpl (Fig. 5D–F). Mineralization assays 
confirmed that EZH2 inhibition reversed the OB differentiation block established by human 
MM1.S transwell co-culture with MC14 cells (Fig. 5G). Our results argue that GFI1 
recruitment of the epigenetic histone modifiers HDAC1 and EZH2 and their actions at the 
mRunx2 histones facilitate the suppressive MM effects on mRunx2 in pre-OB MC4 cells, 
and that this effect is reversible after short-term (48–72 h) MM exposure.
MM induces sustained transcriptional and epigenetic suppression of the hRunx2 promoter 
in human MM patient BMSC that is reversed by HDAC1 or EZH2 inhibition
To demonstrate involvement of MM-induced hRunx2 epigenetic suppression in preventing 
OB differentiation in patients, we used ChIP-qPCR to analyze the activation mark H3K9ac 
at the hRunx2 promoter in BMSC from MM patients (MM-BMSC) and healthy donors (HD-
BMSC). Chromatin isolated from MM-BMSC (n=12) revealed significant reduction of 
H3K9ac at the hRunx2 promoter as compared to HD-BMSC samples (n=6) (Fig. 6A). 
Analysis of additional samples demonstrated that the repressive mark H3K27me3 at the 
hRunx2 promoter was higher on average for MM-BMSC (n=12) as compared to HD-BMSC 
(n=6) (Fig. 6B), though the difference did not reach statistical significance. Therefore, we 
treated MM-BMSC from two patients with vehicle, MC1294, or GSK126 for 7, 14, and 21 
days in osteogenic culture conditions and assayed mineralization/calcium deposition (Fig. 
6C,D). Both MC1294 and GSK126 permitted significantly more OB differentiation as 
compared to vehicle for each MM-BMSC sample. MM-BMSC from three additional 
patients assayed only at 21 days gave similar results (Supplementary Fig. S5A–D). In 
contrast, EZH2 inhibition did not change OB differentiation of HD-BMSC (Supplementary 
Fig. S5E). These data, together with our results from MC4 cells (Fig. 5), demonstrate that 
MM-induced GFI1 recruitment of EZH2 mediates H3K27me3 epigenetic repression of 
Runx2, which contributes to the long-term suppression of hBMSC differentiation into 
functioning OB, and, importantly, that it is reversible even after long-term MM-exposure in 
vivo.
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Discussion
Our studies demonstrate that the key mechanism by which MM cells establish persistent 
suppression of OB differentiation in MMBD (5) is via induction of direct GFI1 binding to 
the Runx2-P1 promoter in pre-OB cells resulting in Runx2 repression. While MM cells 
enhance Runx2 mRNA degradation in proliferating pre-OB, this effect is not sufficient to 
establish OB suppression. MM cells induce GFI1 binding to a novel GFI1 response element 
within the Runx2-P1 promoter. GFI1 then acts as a platform molecule for formation of a 
repressive complex containing histone modifier enzymes HDAC1, LSD1 and EZH2, which 
decrease H3K9ac and H3K4me3 and increase H3K27me3 modifications, respectively, to 
establish a repressive chromatin architecture at Runx2 that is refractory to OB inducer 
activation (Fig. 7). Importantly, we’ve shown that this refractory state requires active 
maintenance and is reversible by inhibition of HDAC1 or EZH2 activity.
We identified a functional GFI1 response element with two overlapped palindromic cores at 
-21/-16, that each contributes to the strength of GFI1 binding. It’s possible that the presence 
of both sides of the palindromic recognition sites generates some cooperative binding, 
although this is unlikely to be through Zn fingers 3–5 of two GFI1 molecules interacting 
with the DNA at the same time due to steric hindrance (19, 35, 36). GFI1 has not been 
reported to dimerize, although other C2H2 Zn finger transcription factors, such as Ikaros, 
TRPS1, and Drosophila Hunchback can homodimerize via the alpha helices of two Zn 
fingers that are not involved in protein-DNA interactions (37). It remains to be established if 
these palindromic sites can induce a pair of GFI1 molecules to bind at the same time, 
perhaps by each only contributing a subset of Zn fingers 3–5.
Gene expression is closely associated with histone exchange and histone post-translational 
modifications, which regulate the states of chromatin compaction and assembly of 
transcription machinery at gene promoters (38). In proliferating pre-OB, we found that the 
Runx2-P1 promoter has a poised bivalent chromatin architecture with moderate levels of 
active histone marks H3K9ac and H3K4me3, as well as the repressive mark H3K27me3, is 
pre-loaded with Pol II, and undergoes a low level of basal transcription detectable by qPCR. 
Many developmental genes have a similar poised promoter architecture that can swiftly 
respond to external stimuli but lacks the transcription elongation properties associated with 
active gene expression (39). Similar to a previous report (40), stimulation of OB 
differentiation induced changes in the Runx2 epigenetic profile (increased H3K36me3, 
H3K9ac, and H3K4me3, and decreased H3K27me3) that were consistent with the expected 
activation of the Runx2 gene.
We found that MM cells induced significant chromatin alterations on the Runx2 gene in pre-
OB cells in proliferation media that included a profound decrease in the activation mark 
H3K9ac together with increased levels of the repressive mark H3K27me3. ChIP-qPCR of 
human BMSC samples from MM patients and healthy donors also revealed significantly 
decreased H3K9ac and a trend towards higher H3K27me3 in MM-BMSC as compared to 
HD-BMSC. H3K27me3 has been reported to be elevated in primary undifferentiated BMSC, 
with removal by the demethylase Jumonji domain-containing protein 3 (JMJD3) required to 
allow Runx2 activation during OB induction (41). Thus, the difference in H3K27me3 levels 
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between MM-BMSC and HD-BMSC after OB differentiation induction would likely be 
larger. In summary, the effect of these MM-induced chromatin changes in proliferating pre-
OB is to make the Runx2 gene refractory to activation by OB differentiation stimulation, 
even in the absence of MM cells, by blocking the normal epigenetic changes induced during 
OB differentiation. Thus, leaving the Runx2 chromatin in a state similar to the 
undifferentiated, proliferating pre-OB in spite of exposure to activation signals.
ChIP-qPCR analysis of MM-MC4 co-culture time courses revealed that GFI1 recruitment to 
the Runx2-P1 promoter is not rapid, taking at least 36 h to become detectable. This result 
supports our previous report that GFI1 translocates from the cytoplasm to the nucleus 
following 5TGM1 MM co-culture or TNFα treatment of more than 24 h (6). MM-induced 
GFI1 recruitment to the Runx2 promoter coincided with an increased presence of LSD1, 
HDAC1, and EZH2, the enzymes responsible for the histone modifications that established 
an epigenetic block to osteoblastogenesis. Ectopic expression of GFI1 in MC4 cells in the 
absence of MM exposure was sufficient to recruit HDAC1 and EZH2, alter the chromatin 
architecture, and repress the Runx2 gene. GFI1 can repress target genes by recruiting 
HDAC1 and LSD1 co-repressors to establish epigenetic silencing in other cell systems (20, 
21), and their presence at Runx2 is consistent with the MM-induced decrease in activating 
marks H3K9ac and H3K4me3, respectively. Of note, LSD1 primarily acts on H3K4me1/2 
substrates (42), but its presence regulating the H3K4 methylation state is primarily 
associated with gene repression and decreased levels of H3K4me3 at promoters (43). We 
made the novel observation that Gfi1 mediates the recruitment of EZH2 to Runx2, 
facilitating deposition of H3K27me3 at the Runx2 promoter. Snail1, another member of the 
SNAG family of zinc finger transcription repressors (44), has also been implicated in 
recruiting components of PRC2 during the repression of the E-cadherin (CDH1) gene in 
tumor cells (45) via the N-terminal repressor SNAG domain.
Studies with MC4 with a stable Gfi1 knockdown demonstrated that lack of GFI1 binding to 
the Runx2 promoter in MM-exposed pre-OB caused diminished recruitment of both HDAC1 
and EZH2, preventing MM-induced H3K9ac loss and H3K27me3 increase on Runx2. These 
changes allowed OB differentiation, as evidenced by increased expression of Runx2 and the 
OB differentiation markers Ocn and Bsp. Interestingly, Gfi1 knockdown did not prevent the 
early MM-induced decrease of Runx2 mRNA. This indicates that destabilization of the 
Runx2 mRNA is not sufficient to repress OB differentiation, and that GFI1-mediated 
chromatin changes are necessary for the MM alteration of pre-OB fate.
Several studies indicate that both HDAC1 and EZH2 are associated with negative regulation 
of osteoblastogenesis. Human mesenchymal stem cells exhibited increased osteogenic 
differentiation due to CDK1 dependent phosphorylation of EZH2, thereby causing 
disruption of PRC2 complex formation on Runx2 and OB-related gene promoters (46). 
Dudakovic et al. (47) reported that human stromal cells from the vascular fraction of adipose 
tissue displayed enhanced OB differentiation if treated with EZH2 inhibitor or shRNA. 
Similarly, down-regulation of HDAC1 activity was shown to promote OB differentiation due 
to hyperacetylation of osteogenic gene promoters (48). Using the selective inhibitors 
MC1294 (HDAC1i) and GSK126 (EZH2i) to treat MC4 cells placed into OB differentiation 
media after 72 h MM exposure, we demonstrated that blockade of either of these epigenetic 
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modifiers rescued expression of Runx2 as well as its downstream target OB genes Ocn, Bsp, 
and Alpl from MM-triggered repression. HDAC1 and EZH2 have a plethora of roles during 
OB differentiation and we observed that the universal targeting of these enzymes was 
slightly repressive on Bsp and Alpl expression in normal OB differentiation samples. 
Despite this effect, the inhibitors had profound positive effects on the expression of these 
genes during OB differentiation after MM exposure. Further, we reported that siRNA 
knockdown of Gfi1 in BMSC isolated from MM patients or after MM exposure of MC4 
cells also rescued the expression of these genes during induction of OB differentiation (6). 
These results suggest that the MM-induced epigenetic suppression of the Runx2 promoter is 
a very dynamic and reversible process that requires continuous maintenance by GFI1 and its 
recruited repressive chromatin modifiers to prevent Runx2 activation by stimulators of OB 
differentiation. How GFI1 remains elevated in MM-BMSC in the absence of MM cells 
remains to be determined.
Here we provide evidence that suppression of the transition of BMSC to functioning OB in 
the pro-inflammatory myeloma BM microenvironment is likely due to Gfi1-mediated and 
maintained epigenetic repression of the key OB differentiation factor Runx2 via recruitment 
of HDAC1 and EZH2. Interfering either with Gfi1 expression or with HDAC1 or EZH2 
activity reverses the epigenetic repression and permits OB differentiation. These results 
suggest that treatment of MM patients with clinically available HDAC1 or EZH2 inhibitors 
may block or reverse the profound OB suppression in MM and allow repair of lytic lesions. 
Understanding the mechanisms associated with the repressive effects of GFI1 in BMSC may 
also lead to the development of novel therapeutics for MMBD, as well as various 
inflammatory diseases such as rheumatoid arthritis, that cause homeostatic imbalance in the 
bone microenvironment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Transcriptional and epigenetic changes at mRunx2 in MM-exposed MC4
(A) Experimental design schematic of 5TGM1 MM-MC4 co-cultures and induction of OB 
differentiation. After 48 h co-culture in proliferation media, the MM cells were removed, 
and the MC4 were either harvested immediately (d0±MM) or first placed in OB 
differentiation media for 4 days (d4±MM). (B) Schematic of mRunx2 qPCR amplicons with 
promoters P1 and P2 indicated (see Table S2 for positional numbering and the primer 
sequences). Amplicon-3 encompasses the Gfi1 binding site. (C–H) ChIP-qPCR analyses of 
RNA Pol II occupancy and several H3 modifications along mRunx2 in MC4 cells treated as 
described in A using qPCR amplicons denoted in B (amplicons not done for a particular 
pull-down are in gray). Enrichment values are plotted relative to amplicons 3 or 7 as 
indicated by underlining, depending upon whether the focus was on the promoter (C, F–H) 
or the body of the gene (D, E): (C) total RNA Pol II; (D) phosphorylated Pol II CTD Ser 2P; 
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(E) elongation mark H3K36me3; (F) activation mark H3K9ac; (G) activation mark 
H3K4me3; and (H) repressive mark H3K27me3. Error bars represent SEM of 3–4 biological 
replicates (2 replicates for H3K9ac d4±MM). Statistically significant comparisons of: ◆;d4-
MM to d0-MM, ■; d0+MM to d0-MM; ★; d4+MM to d4-MM. ⭘ – represents values of 
p<0.08.
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Figure 2. Mutation of the GFI1 cores at -21/-16 mRunx2 relieves ectopic GFI1 and TNFα 
repression of the Runx2 promoter
Reporters -974/+111 mRunx2 promoter-pGL4.10[luc2] WT or containing mutations L, R, or 
LR or the internal deletion Δ-37/-7 (depicted in A) were transfected into MC4 cells either 
(B) with pcDNA3.1 (EV) and pcDNA3.1-mGFI1-WT plasmids or (C) that were treated with 
nothing (Control) or TNFα (0.5 ng/ml) 6 h after transfection. (B, C) Reported luciferase 
activities in harvested (48 h) cell lysates were evaluated with respect to WT reporter either 
(B) cotransfected with EV or (C) the untreated control. (D) Myc-mGFI1-WT, deletion 
constructs which encode mGfi1 aa 1-380 or 239-423, and EV were cotransfected into MC4 
cells with mRunx2-Luc-WT reporter depicted in A, and harvested lysates were analyzed for 
luciferase activities as compared to cells transfected with EV and myc-GFI1 expression by 
Western Blot (shown below graph). Each experiment above was repeated at least three 
independent times.
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Figure 3. Analysis of recruitment to mRunx2 of histone modifier enzymes in MM-exposed or 
GFI1-transfected MC4
(A) Varying amounts of mGFI1-WT and EV plasmids transfected as indicated into MC4 
cells and mGfi1 and endogenous mRunx2 mRNA levels were evaluated by qPCR. (B,C) 
Myc-mGFI1-WT, myc-mGFI1 deletion constructs encoding aa 1-380 or 239-423, or EV 
were transfected into MC4. Transfected cells were analyzed for (B) myc-mGFI1 binding at 
the Runx2 promoter amplicon-3 by ChIP-qPCR using anti-myc Ab and (C) the effect on 
endogenous Runx2 mRNA levels by qPCR with expression of the transfected myc-mGFI1s 
by Western Blot displayed underneath. (D) ChIP-qPCR analysis of endogenous GFI1 
recruitment to the Runx2 promoter amplicon-3 (Fig 1B) in MC4 cells co-cultured with 
5TGM1 MM cells for the indicated times. For all, biological triplicates within two 
separately run experiments were averaged together and the SEM calculated. (E) ChIP-qPCR 
analyses of MC4 cells after MM-exposure per scheme in Fig. 1A (d0±MM) for GFI1 
binding and HDAC1, LSD1, and EZH2 occupancy within the mRunx2 amplicon-3. (F) 
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ChIP-qPCR analyses of ectopic GFI1 recruitment of HDAC1 and EZH2, and consequent 
enhancement of H3K27me3 at the Runx2 promoter in MC4. Error bars represent SEM for 3 
biological replicates except H3K27me3 in F had only two. (B, D–F) Amplicon-7 was used 
as a negative control for GFI1 binding.
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Figure 4. mGfi1 knockdown in MC4 cells prevents MM-induced repression of mRunx2 and OB 
differentiation markers, the recruitment of HDAC1 and EZH2, and repressed chromatin 
architecture acquisition
qPCR analysis of mRNAs from SCR- and shGfi1-MC4 cells treated as described in Fig. 1A 
for: (A) Gfi1, (B) Runx2, (C) Ocn, (D) Bsp, and (E) Alpl mRNA expression. ChIP-qPCR 
analyses of MM-induced recruitment to the Runx2 promoter of (F) GFI1, (G) HDAC1, and 
(H) EZH2 and enrichment profiles for (I) H3K9ac and (J) H3K27me3 in SCR and shGfi1-
MC4 at d0±MM. IgG ChIP was run on SCR-MC4 cells. Error bars represent SEM for (A–E) 
3–4 or (F–J) 2 biological replicates ⭘ – represents values of p<0.08. Amplicons as indicated 
in Fig 1B.
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Figure 5. Inhibition of histone modifiers HDAC1 and EZH2 rescues OB differentiation of MM-
exposed MC4 cultures
(A–F) MC4 cells were exposed to 5TGM1 MM cells as diagrammed in Fig 1A in the 
absence of inhibitors. After MM removal at d0, the MC4 were cultured in OB differentiation 
media for 2 to 4 days with either DMSO vehicle, MC1294 (10 μM), or GSK126 (5 μM) 
added as indicated. (A,B) The effects of the inhibitors (A) MC1294 (HDACi) and (B) 
GSK126 (EZH2i) on global levels of H3K9ac, H3K27me3, H3, HDAC1, EZH2 levels in 
MC4 cells on day 2 were assessed by Western blot using antibodies as indicated. (C–F) 
Effects of the inhibitors MC1294 and GSK126 on (C) Runx2, (D) Ocn, (E) Bsp, and (F) 
Alpl mRNA expression during differentiation of control and 5TGM1 MM-exposed MC4 at 
day 0 (no inhibitor) or after 4 days of differentiation (d0±MM, d4±MM). Error bars 
represent SEM for 3 biological replicates. (G) Human MM1.S MM cells in transwells (or 
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empty control transwells) were co-cultured with MC14 cells for 72 h. Following transwell 
removal, the MC14 cells were cultured in osteogenic media +/- GSK126 (2.5 μM) and 
mineralization was assessed using Alizarin Red staining at d21; the GSK126 was absent 
d14–21. Shown is density quantitation for the average of 6 wells with SEM and significance 
indicated.
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Figure 6. MM-BMSC samples exhibited decreased H3K9Ac at the hRUNX2 promoter compared 
to HD-BMSC and inhibition of either HDAC1 or EZH2 rescues MM-BMSC OB differentiation
(A) Anti-H3K9Ac (and IgG) ChIP-qPCR analysis of HD-BMSC (N) (n=6) and MM-BMSC 
(MM) (n=12, patient characteristics in Table S3) using amplicons +185 and +66065 relative 
to the hRUNX2 P1 TSS. One anti-H3K9Ac ChIP amplicon +185 N sample result was used 
as the reference sample for all other data and ΔΔCt shown. (B) Anti-H3K27me3 (and IgG) 
ChIP-qPCR analysis of HD-BMSC (n=6), which included two donors used in A, and a 
unique set of MM-BMSC (n=12, patient characteristics in Table S4), using amplicons -97 
and +66065 as described in A. There were no significant differences in the IgG pulldown 
results across all samples and between the amplicons. The significance of differences 
between N and MM samples for each amplicon were determined by one-way ANOVA with 
Tukey’s multiple comparison post-test using Graphpad Prism 6. (C, D) MM-BMSC from 
two different patients (Table S5) were cultured 7, 14, or 21 days in osteogenic media 
supplemented with vehicle, MC1294 (10 μM) or GSK126 (2.5 μM); the inhibitors were 
absent d14–21. Mineralization was assessed using Alizarin Red staining. Three independent 
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wells from each treatment group are shown as well as a representative 5X magnification. 
Below each set is the density quantitation for the average of 6 wells/condition with SEM and 
significance indicated.
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Figure 7. Schematic of the mechanism of GFI1-induced epigenetic repression of the Runx2 locus 
in MM exposed pre-OB
In proliferating pre-OB cells, Runx2-P1 is in a poised bivalent configuration with paused Pol 
II and prominent levels of activation-ready promoter chromatin marks H3K4me3 and 
H3K9ac, as well as H3K27me3, with low levels of basal transcription. OB differentiation 
induction stimulates increased accumulation of these active chromatin marks, as well as 
release of Pol II into the Runx2 structural region as marked by increased Pol II Ser2P-CTD 
and accumulation of the H3K36me3 mark. MM exposure acts in a dual mode to repress 
Runx2 expression. The rapid TNFα-induced decrease in Runx2 mRNA is mediated by 
increased mRNA degradation. However, this is insufficient to block induction of OB 
differentiation. The sustained suppression of OB differentiation requires modifications of the 
Runx2 chromatin architecture. GFI1 binds to Runx2 and facilitates recruitment of histone 
Adamik et al. Page 26
Mol Cancer Res. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
co-repressors HDAC1, LSD1 and EZH2, which results in decreased active H3K9ac and 
H3K4me3 and increased repressive H3K27me3 chromatin marks, causing an epigenetic 
block refractory to transcriptional activation in response to OB differentiation signals. 
Inhibition of either HDAC1 or EZH2 can reverse the inhibition and allow OB differentiation.
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